BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤$24.0 million Q3 net loss, versus $16.0 million loss year over year
- ➤$21.9 million Q3 R&D expenses, up from $14.7 million
- ➤FDA aligned on 50 mg twice-daily Phase 2 dose for BH-30643
- ➤SOLARA-2 pivotal Phase 2 trial targets first patient dosing in Q1 2027
- ➤$224.9 million cash and equivalents; runway expected into Q2 2028
Expert Statements
J. Jean Cui, Founder, President and Chief Executive Officer of BlossomHill Therapeutics
“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial.”
J. Jean Cui, Founder, President and Chief Executive Officer of BlossomHill Therapeutics
“We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI”
J. Jean Cui, Founder, President and Chief Executive Officer of BlossomHill Therapeutics
“In parallel, we continue to advance the development of novel, small molecule medicines in our portfolio.”
J. Jean Cui, Founder, President and Chief Executive Officer of BlossomHill Therapeutics
“We recently presented preclinical data on BH-501284, our novel, pseudo-irreversible, Switch-II pan-KRAS inhibitor, that demonstrated sustained KRAS pathway suppression and deep and durable antitumor activity across multiple KRAS-mutant tumor models.”
J. Jean Cui, Founder, President and Chief Executive Officer of BlossomHill Therapeutics
“An IND filing is planned for the first quarter next year.”
J. Jean Cui, Founder, President and Chief Executive Officer of BlossomHill Therapeutics
“We also plan to present translational data with clinical validation of BH-30236's mechanism of action at the American Society of Hematology Annual Meeting in December, reinforcing our belief in its potential to address a significant unmet need in patients with myeloid malignancies.”
Alignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to date
Announced SOLARA-2, the single-arm pivotal Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027
Get started
Create a free account to read the full story.